Tag Archives: drug pricing
Outcomes-based pricing agreements may both improve access to treatments for patients who derive the greatest benefits from them and strengthen pharmaceutical companies’, clinicians’, and insurers’ interest in discouraging the use of ineffective therapies. However, stakeholders are missing...
April 3, 2017
A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option
A new form of “conditional approval” could accelerate the approval of new drugs and, at the same time, take at least a small step towards reducing the costs of potentially life-saving drugs.
March 20, 2017
The pharmaceutical industry often explains that the higher prices they charge in the US provide them with the funds they need to conduct their high-risk research. This claim is empirically testable.
March 7, 2017
Policies giving federal and state governments authority to set drug prices or limit price increases could have the unintended consequence of reducing the incentive to develop more effective drugs. However, certain regulatory reforms can address these concerns and encourage more robust...
July 11, 2016
The public backlash to the pricing of high-value specialty drugs suggests American society is not comfortable with the idea of value pricing in health care. At its extreme, value pricing can extract enormous prices from seriously stricken patients or their insurers, because better health and...
June 1, 2016
Medicare Part D premiums have been flat in recent years but will increase by 13 percent from 2015 to 2016. Given these rising costs, a growing number of policymakers believe the government should be allowed to negotiate drug prices in Medicare Part D.
February 1, 2016
With the growing importance of pharmaceuticals, Anthem and Eli Lilly identified two areas that we believe must be addressed in order to unleash a new wave of innovative approaches to pharmaceutical pricing.
January 29, 2016
The FDA's approval this year of the first biosimilar has prompted a flurry of regulatory activity. Key concerns raised by recent FDA guidance remain, as well as other widely anticipated but yet-to-be released regulatory activity, such as the pivotal interchangeability standard.
December 14, 2015